Dr. Axel Gille, President
The medical cannabis business in Europe is expanding rapidly. The dominoes are falling: medicinal and cannabis programs are being adopted by an increasing number of countries across Europe and the world. Europe has a unique opportunity to legislate from the top down and create meaningful and transparent programs that benefit patients while also supplying p harma-grade input extracts to the industry. Danish horticulture enterprise is set to become Europe’s biggest producer of medical cannabis. To this end, Aurora Nordic Cannabis A/S is a subsidiary of Aurora Cannabis Inc., a global leader in the cannabis industry serving both medical and consumer markets and dedicated to helping people improve their lives. The high-tech cultivation facility in Odense, Denmark will supply the fast-moving European medical cannabis market. With more than 9,200 m2 production space and an output of approximately 10,000 kg of high-quality medical cannabis per year, the Aurora Nordic facility is well positioned to service European and international markets.
Furthermore, cannabis oil is made from the extract of dried cannabis flowers. The extraction process is mostly done with CO2 and heating. The process is carried out as gently as possible to preserve as many terpenes and cannabinoids as possible. The extract is mixed into carrier oil, and this is checked to ensure that the strength and composition are uniform from production to production. The medical cannabis pilot program entered into force on 1 January 2018. The program allows doctors to prescribe a new type of cannabis product not previously legal in Denmark.
The purpose of the pilot program is to offer patients a legal way to try treatment with medical cannabis where authorised medicines have not worked. The pilot program is intended to provide a better basis for evaluating the use of medical cannabis at the end of the trial period.
Aurora Nordic recently received its European Union Good Manufacturing Practice approved by the Danish Medicines Agency (Lægemiddel-styrelsen) of the Danish Health Authority (Sundhedsstyrelsen). The EU GMP certification recognizes superior levels of quality in both products and services. This crucial step allows Aurora to manufacture and export EU GMP-graded medical cannabis products from Denmark to other international markets in accordance with local medical cannabis regulations. Dried flower will be the first of severalproducts exported from the Danish facility, with expanded product offerings expected to follow in the near term.
We set the standard in the industry by producing medical cannabis per year of the highest quality
Aurora Nordic was founded as a joint venture between the Danish nursery Alfred Pedersen & Søn, with a history of efficient, quality-oriented horticultural operations and Aurora Cannabis Inc. Aurora Cannabis Inc. competences encompass all aspects of cannabis production such as breeding, cannabis cultivation, formulation and extraction, distribution, research and development. Alfred Pedersen & Søn has entered into a joint venture with Aurora – the world’s second-largest producer of medical cannabis with a series of group-affiliated companies focused on research, product development, cultivation systems and quality cultivation. Additionally, Aurora also views Alfred Pedersen & Søn as an efficient business partner due to the matching values and the Danish nursery’s size and expertise in the European market, where the Funen-based nursery – with a greenhouse capacity of more than 250,000 m².
Aurora is also a major investor in Cann Group Limited, the first licensed Australian producer of medical cannabis. In addition, Aurora owns the German-based Pedanios, a market-leading distributor of medical cannabis in the EU, as well as BC Northern Lights Ltd and Urban Cultivator Inc., which are market leaders in the production and sale of systems for indoor cultivation and other products. Aurora Cannabis Enterprises will own a 51% shareholding in Aurora Nordic Cannabis A/S.
Aurora Europe, headquartered in Berlin, Germany is making strides in serving the medical and consumer markets. Going forward, the firm will continue to bring high-quality, premium medical cannabis to patients worldwide.